Medomet en es it fr

Medomet Brand names, Medomet Analogs

Medomet Brand Names Mixture

  • No information avaliable

Medomet Chemical_Formula


Medomet RX_link

Medomet fda sheet

Medomet FDA

Medomet msds (material safety sheet)

Medomet MSDS

Medomet Synthesis Reference

No information avaliable

Medomet Molecular Weight

1270.28 g/mol

Medomet Melting Point

No information avaliable

Medomet H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Medomet State


Medomet LogP

No information avaliable

Medomet Dosage Forms

Powder for solution (for injection)

Medomet Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Medomet Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Medomet Absorption

No information avaliable

Medomet side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Medomet Patient Information

No information avaliable

Medomet Organisms Affected

Aspergillis, Candida and other fungi